Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department has taken to respond to concerns raised by the Competition and Markets Authority on the pricing of (a) hydrocortisone tablets and (b) liothyronine tablets since 2016.
Concerns about potential drug pricing abuses are a matter for the Competition and Markets Authority (CMA). The CMA has several ongoing investigations into excessive prices of generic medicines. Where it has concern about the price of a generic medicine, the Department asks the CMA to investigate that price.